621 A Phase I Dose-escalation Study of MFGR1877S, a Human Monoclonal Anti-fibroblast Growth Factor Receptor 3 (FGFR3) Antibody, in Patients (pts) with Advanced Solid Tumors

Authors :: Elaine T. Lam
K. Shih
O. Kabbarah
P. ODonnell
Michael S. Gordon
J.W. Goldman
D. Lu
I. Rooney
W. Ho
Y.J. Choi
Source :: European Journal of Cancer. 48:191-192
Publication Year :: 2012
Publisher :: Elsevier BV, 2012.

Subjects :: Cancer Research
biology
business.industry
Fibroblast growth factor receptor 3
Oncology
Phase (matter)
Monoclonal
Dose escalation
Cancer research
biology.protein
Medicine
In patient
Antibody
business

Tools